

The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes

Tuesday, December 13, 2022

8:00 AM

EOHHS, Virks Building
3 West Road, Cranston, RI 02920



P & T Members Present:

Todd Brothers, PharmD
Nickolai Morin, PharmD
Tracey Taviera, PharmD
Bill Quirk, RPh
Greg Allen, MD

Absent:

Dezeree Hodish, Assistant Director Financial and Contract Management (EOHHS)
Karen Mariano, RPh (Gainwell Technologies)
Matt Salisbury, MD
Rick Wagner, MD

Others Present:

Ann Bennett, MHA (Gainwell Technologies)
Jerry Fingerut, MD, Medical Director, (EOHHS)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance – 8:07 am. Chairperson Tracey Taviera called the meeting to order and asked for introductions of the committee and those supporting the meeting. The September 20, 2022 draft meeting minutes will be reviewed at the April 2023 Meeting.

Public testimony included the following speakers and topics.

Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

P & T Speakers	Affiliation	Topic
Mark Golick	Neurocrine Biosciences	Ingrezza
Zachary Rideman	United Therapeutics	Tyvaso
Annie Vong	Abbvie	Vraylar
Arlene Mejia	Pierre Fabre	Hemangeol
Michael Boskello	Alkermes	Aristada/Initio

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee. MMA reminded the audience that Medicaid covers all medications as long as the manufacturer has signed a contract with CMS even if it is not on the PDL. FFS RI Medicaid is secondary on many claims therefore the PDL compliance in some classes is not always the best due to other insurance paying the majority of the claim which allows it to bypass PDL rules. Also, informed the audience that this meeting and the Preferred Drug List is strictly for FFS RI Medicaid, not any of the Managed Care Organizations. MMA Addressed the shortage issue of certain drugs stating FFS RI Medicaid makes allowances for other options.

Therapeutic Categories		Comments & Discussion	Vote: Yes	Vote: No	Abstain	Motion
Cardiovascular	Angiotensin Modulators & combinations		4	0	0	Passes
	Antianginal & Anti-Ischemic		4	0	0	Passes
	Anticoagulants		4	0	0	Passes
	Beta-Blockers		4	0	0	Passes
	Calcium Channel Blockers		4	0	0	Passes
	Lipotropics, Others		4	0	0	Passes
	Lipotropics, Statins		4	0	0	Passes
	PAH Agents, Oral And Inhaled		4	0	0	Passes
	Platelet Aggregation Inhibitors		4	0	0	Passes
CNS	Alzheimer's Agents		4	0	0	Passes
	Anticonvulsants		4	0	0	Passes
	Antidepressants, Others		4	0	0	Passes
	Antidepressants, SSRIs		4	0	0	Passes
	Antiparkinson Agents		4	0	0	Passes
	Antipsychotics		4	0	0	Passes
	Movement Disorders		4	0	0	Passes
	MS Agents		4	0	0	Passes
	Neuropathic Pain		4	0	0	Passes
	Sedative Hypnotics		4	0	0	Passes
	Antihypertensives, Sympatholytics		4	0	0	Passes
	Stimulants and Related Agents		4	0	0	Passes
Tentative New Categories	HAE Treatments		4	0	0	Passes
	Hemophilia Treatments	All products are preferred at this time.	4	0	0	Passes
	Vasodilators, Coronary		4	0	0	Passes

Next Meeting

Tuesday, April 4, 2023

Meeting schedule for next year:

April 4, 2023

June 6, 2023

September 12, 2023

December 12, 2023

Adjournment

The meeting adjourned at 9:04 AM